NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...
top of page
- Sep 23, 2022
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
(MajesTEC-7) Newly diagnosed Multiple Myeloma NCT05552222: Phase 3: A Study to Compare Teclistamab in Combination With Daratumumab and...
268
- Sep 1, 2022
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide...
92
- Sep 1, 2022
NCT05461209: Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)
(MonumenTAL-5) NCT05461209: Phase 3: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory...
99
- Apr 26, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...
116
- Apr 21, 2022
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)
NCT05338775: Phase 1: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor...
54
- Mar 1, 2022
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
MASTER-2 NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2) NCT05231629: Phase 2:...
148
- Mar 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and...
786
- Mar 1, 2022
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel NCT05201781: Phase 4: A...
55
- Mar 1, 2022
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
EMN30 - MajesTEC-4 64007957MMY3003 NCT05243797: Phase 3: Teclistamab + Lenalidomide Versus Lenalidomide Alone in NDMM Myeloma as...
560
- Mar 1, 2022
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma
NCT05218603: Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone...
60
- Dec 16, 2021
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)...
35
- Dec 16, 2021
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple...
334
- Dec 11, 2021
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory...
63
- Dec 3, 2021
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
MajesTEC-3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and...
747
- Jun 26, 2021
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...
139
- Jun 11, 2021
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...
1,441
- Jun 9, 2021
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...
600
- Jun 3, 2021
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
Phase 1 Relapsed & Refractory Myeloma A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma The...
350
- Dec 29, 2020
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...
748
- Dec 17, 2020
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide...
67
- Dec 10, 2020
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
MajesTEC1 study A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1) Relapsed & Refractory...
694
- Dec 4, 2020
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
Talquetamab and Teclistamab Daratumumab A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or...
434
- Jul 18, 2020
NCT04407442: Phase 2: Dara, Azacitidine & Dex for RRMM Myeloma Previously Treated With Daratumumab
NCT04407442: Phase 2: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma...
86
- Jul 16, 2020
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
D-ClaPd NCT04302324: Phase 2: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple...
46
- Jul 8, 2020
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure
NCT04352205: Phase 2: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205:...
26
- Dec 30, 2019
NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...
505
- Dec 28, 2019
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
CARTITUDE-4 Ciltacabtagene Autoleucel A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA),...
1,069
- Dec 19, 2019
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
630
- Dec 19, 2019
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis...
17
- Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
603
- Dec 14, 2019
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...
447
- Dec 14, 2019
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Dara-KPd This research study is studying the...
198
- Dec 13, 2019
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...
180
- Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
LocoMMotion Relapsed & Refractory Multiple Myeloma NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed...
137
- Dec 11, 2019
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
TRIMM-2 study A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment...
1,008
- Dec 6, 2019
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed...
112
- Dec 6, 2019
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...
23
- Dec 6, 2019
NCT03871829: Phase 2: Retreatment in Participants With Myeloma Who Have Been Previously Rx with Dara
54767414MMY2065 NCT03871829: Phase 2: Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With...
64
- Dec 31, 2018
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...
214
- Dec 30, 2018
NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS
CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...
758
- Dec 26, 2018
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...
577
- Dec 15, 2018
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
Perseus Study NDMM Newly Diagnosed Multiple Myeloma EMN 17 Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to...
684
- Dec 14, 2018
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...
441
- Dec 12, 2018
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)
The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells. CHINESE STUDY A...
297
- Dec 7, 2018
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
MonumenTAL-1 study A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific...
591
- Dec 7, 2018
NCT03556332: Phase 2 - Carfilzomib, Lenalidomide, Dex Daratumumab for relap. MM with auto transplant
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous...
234
